Iodine-123-MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics

Kakuigaku

Volumn 36, Issue 8, 1999, Pages 827-834

  Okuyama, Chio ^a   Ushijima, Yo ^a   Watanabe, Kaori ^a   Sugihara, Hiroki ^a   Nishimura, Tsunehiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

123I MIBG activity; Catecholamine metabolites; Histopathological type; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; HOMOVANILLIC ACID; IODINE 123; VANILMANDELIC ACID;

ARTICLE; CANCER GRADING; CATECHOLAMINE URINE LEVEL; CHILD; CLINICAL ARTICLE; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; NEUROBLASTOMA; RADIOISOTOPE DISTRIBUTION; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; BIOLOGICAL MARKERS; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOVANILLIC ACID; HUMANS; INFANT; INFANT, NEWBORN; IODINE RADIOISOTOPES; MALE; MEDIASTINAL NEOPLASMS; NEOPLASM STAGING; NEUROBLASTOMA; RADIOPHARMACEUTICALS; VANILMANDELIC ACID;

EID: 0032697398     PISSN: 00227854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 131I) metaiodobenzylguanidine. J Nucl Med 1980; 21: 349-352.
2. Shapiro B: Imaging of catecholamine secreting tumors: use of MIBG in diagnosis and treatment. Baillieres Clin Endocrinol Metabol 1993; 7: 491-507.
3. 123I]Iodobenzylguanidine: Concise communication. J Nucl Med 1984; 25: 436-440.
4. Shulkin BL, Shapiro B: Current Concepts on the Diagnostic use of MIBG in Children. J Nucl Med 1998; 39: 679-688.
5. Maurea S, Lastoria S, Caraco C, Indolfi P, Casale F, Tullio MT, et al: Iodine-131-MIBG Imaging to Monitor Chemotherapy Response in Advanced Neuroblastoma: Comparison with Laboratory Analysis. J Nucl Med 1994; 35: 1429-1435.
6. Geatti O, Shapiro B, Sisson JC, Hutchinson RJ, Mallete S, Eyre P, et al: Iodine-131 Metaiodobenzylguanidine Scintigraphy for the Location of Neuroblastoma; Preliminary Experience in Ten Cases. J Nucl Med 1985; 26: 736-742.
7. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH: Malignant pheochromocytoma clinical, biochemical and scintigraphic characterization. Clin Endocrinol 1984; 20: 189-203.
8. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PMG, Ross G, et al: Uptake of Iodine-123-MIBG by Pheochromocytomas, Paragangliomas, and Neuroblastoma: Histopathological Comparison. J Nucl Med 1987; 28: 973-978.
9. Misugi K, Misugi N, Newton WA: Fine structural study of neurobalstoma, ganglioneuroblastoma, and pheochromocytoma. Arch Path 1968; 86: 160-170.
10. Hicks MJ, Mackay B: Comparison of Ultrasound Structural Features Among Neuroblastic Tumors: Maturation from Neuroblastoma to Ganglioneuroma. Ultrastruct Pathol 1995; 19: 311-322.
11. Yokoyama M, Okada K, Tokue A, Takayasu H, Yamada R: Ultrastructural study of neuroblastoma. Invest Urol 1971; 9: 156-164.
12. Lucas K, Gula MJ, Knisely AS, Virgi MA, Wollman M, Blatt J: Catecholamine Metabolites in Ganglioneuroma. Med Pediatr Oncol 1994; 22: 240-243.
13. Candito M, Soler C, Derille A, Bekvi S, Chamlon P, Thyss A: Urinary Excretion of Methylated Catecholamine Metabolites in a Child with Neuroblastoma Maturing into Ganglioneuroblastoma. Med Pediatr Oncol 1996; 26: 57-60.
14. Liebhart M: Histopathological features of neoplasms of the neuroblastoma group after complex antineoplastic treatment. Patol Pol 1981; 32: 395-107.